Supplying the future
of precision longevity
KRECE is a precision longevity brand launching across Latin America and Spain. We are actively selecting manufacturing and formulation partners for our SIGNALS peptide line. We prioritize quality documentation, long-term reliability, and partners who understand that our end customer is a medical professional or a sophisticated biohacker — not a mass-market consumer.
What we are building
KRECE is a precision longevity company developing evidence-based peptide protocols for the Latin American and European markets. Our product line — SIGNALS by KRECE — is positioned at the intersection of functional medicine, cosmetic science, and high-performance wellness. We sell through B2B medical channels (aesthetic clinics, functional medicine physicians, compounding pharmacies) and premium direct-to-consumer via e-commerce.
We are entering a Latin American market that is currently underserved by quality, documented peptide products. Most competitors either sell research chemicals with no quality guarantees or pharmaceutical-grade products at prohibitive price points. KRECE occupies the middle ground: premium quality with rigorous documentation, at a price accessible to the target professional and biohacking segment. The EU-MERCOSUR free trade agreement (in force May 2026) significantly improves our logistics and expansion economics.
Products we are sourcing now
Anxiolytic neuropeptide. Intranasal aqueous solution. 300–500 mcg per actuation. 10ml metered spray bottle. Isotonic saline base, pH 5.5–6.5.
Intranasal · 10mlNootropic neuropeptide, BDNF upregulation. Intranasal spray. 150–300 mcg per actuation. Same format as SIGNAL 04. These two products ship as a rotation protocol.
Intranasal · 10mlCopper Tripeptide-1 at 0.5–2% in liposomal delivery system. Characteristic blue color. pH 6.0–7.0. Paraben-free. 30ml glass dropper bottle. Premium cosmetic-grade.
Topical · 30mlSame active compound as SIGNAL 05, different vehicle and application format. 50ml precision scalp applicator bottle. Targeting androgenetic alopecia and diffuse hair loss.
Topical · 50mlAlpha-MSH tripeptide, anti-inflammatory gut protocol. Enteric-coated capsules. Paired with Tributyrin and L-Glutamine cofactor kit. B2B gastroenterology channel.
Oral · Capsule kitGrowth hormone secretagogue stack. Subcutaneous injectable, lyophilized powder with bacteriostatic water. 5mg vials. B2B anti-aging and sports medicine channel.
Injectable · SubQNon-negotiable requirements for all partners
Our expansion roadmap
KRECE is building a multi-market distribution network across Latin America and Europe. Partners who qualify at the pilot stage have the opportunity to grow with us as we expand. Our 24-month volume projections are 5,000–20,000 units per SKU across active markets.
| Phase | Timeline | Markets | Est. monthly units per SKU |
|---|---|---|---|
| Pilot validation | Months 1–3 | Paraguay · Uruguay | 50–150 units |
| Phase 1 launch | Months 3–12 | PY · UY · AR · CL · CO | 200–500 units |
| Phase 2 expansion | Year 2 | + Spain · Mexico | 500–1,500 units |
| Phase 3 scale | Year 3+ | Full LATAM + EU | 1,500+ units |
What we offer our manufacturing partners
We are building a catalog of 12+ SKUs with recurring production cycles. Partners who qualify at the pilot stage become preferred suppliers for all subsequent products in their category. We do not shop for the cheapest option on each order.
We come to every conversation with detailed product specifications, not vague requests. Our team understands peptide chemistry, formulation requirements, and regulatory documentation. You will not spend time educating us on basics.
KRECE products sell at $90–$300 USD per unit. We are not optimizing for the lowest possible COGS — we are optimizing for the best quality-to-documentation ratio. Partners who invest in quality CoA and formulation receive better pricing terms from us.
With the EU-MERCOSUR free trade agreement entering provisional force on May 1, 2026, tariffs on pharmaceutical and cosmetic ingredients between our markets will progressively decrease. Partners positioned now benefit from improved supply chain economics as the agreement phases in.
Our founder has full geographic mobility and is available to visit facilities in China, India, and Europe. We consider factory visits part of the qualification process, not an exception. Partners who welcome site visits move faster through our qualification pipeline.
We evaluate 3–4 partners per product category in parallel. Our decision timeline from initial email to pilot order is typically 6–10 weeks. We provide feedback to all evaluated suppliers regardless of outcome, because we may return to you for a different product category.
How we select partners
Reply to our email with your capabilities, certifications, and a CoA sample from a recent relevant batch. Response time within 48 hours is a strong positive signal.
30–45 minute video call to review specifications, MOQ, pricing structure, lead times, and documentation package. We will ask specific technical questions.
We order a sample batch (1–5g for raw materials, 10–20 units for finished products). Samples are tested by an independent third-party laboratory. CoA verification is mandatory.
If sample testing passes, we proceed to a pilot production order of 100–200 units. Successful pilot qualifies the partner for all future orders in their product category.
Send us an email describing your capabilities, the products from our pipeline you can manufacture, and attach a representative CoA from a recent batch. We respond to all qualified inquiries within 48 hours.